Drugs / Processed Amniotic Fluid
Processed Amniotic Fluid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04438174 | Aug 2022 → Mar 2023 | — | University of Utah | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03298815 Comparator | Dec 2019 → Dec 2022 | chronic graft versus host disease | University of Utah | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Processed Amniotic Fluid | “with Processed Amniotic Fluid (pAF) Drops.” NCT03298815 ↗ |
| Known as | pAF | “with Processed Amniotic Fluid (pAF) Drops.” NCT03298815 ↗ |
| Known as | Processed Amniotic Fluids (pAF) | “Processed Amniotic Fluids (pAF)” NCT04438174 ↗ |
| Route | Topical | “One drop (0.25 mL) in one eye twice daily for up to 3 months” NCT03298815 ↗ |